Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.6400+0.0100 (+0.28%)
At close: 04:00PM EDT
3.6800 +0.04 (+1.10%)
After hours: 04:53PM EDT
Advertisement

iCAD, Inc.

98 Spit Brook Road
Suite 100
Nashua, NH 03062
United States
603 882 5200
https://www.icadmed.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees136

Key Executives

NameTitlePayExercisedYear Born
Ms. Stacey M. StevensPres, CEO & Director484.83kN/A1969
Mr. Jonathan GoChief Technology Officer416.34kN/A1963
Mr. Michael S. KleinExec. Director621.02kN/A1954
Mr. Charles Ross CarterCFO & Sec.N/AN/A1967
Ms. Annette L. HerouxVP of Admin.N/AN/A1957
Brian TestaChief People OfficerN/AN/AN/A
Mr. Jeffrey SirekChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Corporate Governance

iCAD, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement